Here, we confirmed that stable expression of B-cell lymphoma-xL (Bcl-xL) in N18TG neuroglioma cells could suppress c-Jun N-terminal protein kinase (JNK) activation, nuclear fragmentation, and cell death caused by etoposide treatment. Moreover, additional overexpression of JNK1 led to partially antagonize the antiapoptotic environment attained by Bcl-xL, implying that JNK1-involved pathway may play a role in down-regulation of the antiapoptotic effect of Bcl-xL. However, the antagonistic effect of JNK1 on the antiapoptotic action of Bcl-xL was significantly weaker than that on the action of Bcl-2. Interestingly, we found that overexpression of JNK1 led to increase of Bcl-xL expression. Thus, these results suggest that Bcl-xL and Bcl-2 may induce its antiapoptotic effect in a different mechanism, provoking the possibility of involvement of JNK1-involved pathway in Bcl-xL expression.
Apoptosis, or physiological cell death, is an ATP-requiring cell elimination program during which the cells show characteristic morphological changes that include chromatin condensation and packaging of nuclear fragments into small apoptotic bodies, which are eliminated by neighboring cells through phagocytosis without eliciting inflammatory reactions. 1) Apoptotic process is tightly organized and its dysregulation causes a wide array of diseases, including cancer, neurodegenerative disorders, autoimmune diseases, heart diseases, diabetes, and other disorders.
Several key players and mechanisms of apoptosis have been elucidated. Caspase cascade is one of the most important systems for apoptotic process. Moreover, recent studies have shown that one of the important phosphorylation-dephosphorylation apoptotic signaling cascades is composed of mitogen-activated protein kinases (MAPKs). Up to now, several distinct MAP kinases have been identified; p42/p44 extracellular signal-related kinases (ERK1 and 2), 2) c-Jun Nterminal protein kinase (JNK)/stress-activated protein kinase (SAPK), 3) p38 MAP kinase, 4) and big MAPK (BMK1/ ERK5). 5, 6) The activation of JNK/SAPK and p38 MAPK is generally associated with promotion of apoptosis. 7) Three mammalian JNK genes (jnk1, jnk2, jnk3) have been identified and alternative splicing of them generates many different isoforms. 8) JNK is required for embryonic morphogenesis and contributes to the regulation of cell proliferation and apoptosis. 9) Although their key role seems to be the regulation of transcription factor activity, the mechanisms by which JNK signaling pathways modify the rate of apoptosis were not fully elucidated.
Apoptotic stimuli also induce an alteration in the permeability of the mitochondrial membranes, progressive mitochondrial swelling and outer mitochondrial membrane rupture resulting in cytochrome c (Cyt c) translocation from the intermembrane space to the cytoplasm. 10) The released Cyt c in turn activates death-driving proteases known as caspases. The antiapoptotic or proapoptotic B-cell lymphoma-2 (Bcl-2) family proteins regulate cell death by controlling this mitochondrial membrane permeability and the release of Cyt c during apoptosis. 11) Shimizu et al. (1999) showed that proapoptotic proteins, Bax and Bak, accelerate the opening of VDAC (voltage-dependent anion channel), a primary transporter of ions and metabolites across the outer mitochondrial membrane, whereas the antiapoptotic protein, Bcl-xL closes VDAC by binding to it directly. 12) The bcl-x gene, a bcl-2-related apoptosis-regulatory gene, was shown to produce two protein products, Bcl-xL and Bcl-xS by alternative mRNA splicing mechanism. 13) Expression of Bcl-xL showed inhibition of cell death, while that of the smaller mRNA, bcl-xS enhanced cell death by inhibiting Bcl-2 activity.
For better understanding of the complex apoptotic mechanism, the relationship between several apoptotic players should be studied carefully. Since Bcl-2 had been first identified as survival gene involved in the control of apoptosis, 14) more than 15 Bcl-2 family members, representing both antiapoptotic and proapoptotic members, have been characterized to date. 15) Although several potential mechanism(s) by which Bcl-2 family proteins function was suggested, the exact mechanism(s) is still unclear. In the present study, we investigated the relationship between JNK1 activation and Bcl-xL expression in neuroglioma N18TG cells. We showed that expression of Bcl-xL blocked the JNK1 activation induced by etoposide treatment and the antiapoptotic effect of Bcl-xL was partly, but not completely, antagonized by JNK1 overexpression. Our results suggest that the JNK1-involved pathway may differentially regulate the antiapoptotic action of Bcl-xL and Bcl-2 in neuroglioma N18TG cells, prompting the possibility of involvement of JNK1 in Bcl-xL expression.
MATERIALS AND METHODS
Cell Culture For the culture of neuroglioma N18TG cells, we used poly-D-lysine-coated plates containing Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum and 100 U/ml of penicillin/streptomycin (Life Technologies, Inc.). Cells were maintained under a humidified atmosphere of 5% CO 2 at 37°C.
Transfection Cells were plated in 100 mm dishes, grown overnight, and transfected with pcDNA3-bcl-xL, pCEP4-JNK1, pcDNA3-bcl-2, or pCEP4-JNK1-DN (dominant negative mutant) using LipofectAMINE (Life Technologies, Inc.). After 48 h of transfection, cultures were maintained in the complete medium containing 500 mg/ml of G418 (for pcDNA3-bcl-xL) or 200 U/ml of hygromycin (for pCEP4-JNK1) to select the cell lines stably expressing Bcl-xL or JNK1, respectively. Stable N18/Bcl-xL, N18/JNK1, N18/ Bcl-xL/JNK1, N18/Bcl-2, N18/Bcl-2/JNK1 or N18/JNK1-DN clones were characterized by Western blot analysis using anti-Bcl-xL or anti-JNK1 antibody (Pharmingen).
Western Blot Analysis For measuring the expression level of Bcl-xL or JNK1, cells were washed with ice-cold PBS and lysed in a buffer containing 50 mM Tris-HCl, pH 7.0, 2 mM EDTA, 1% Triton X-100, 2 mM PMSF, 10 mg/ml leupeptin and aprotinin for 15 min. Lysates were centrifuged at 13000 g for 15 min at 4°C and the supernatants were subjected to sodium dodecyl sulfate (SDS)-PAGE. After gel electrophoresis, the separated proteins were blotted onto membrane filters and processed for western blot analysis using appropriate antibody. Specific bands were detected by enhanced chemiluminescence system (Amersham Pharmacia Biotech.) as recommended by the manufacturer.
Cell Viability Assay Cultured cells were exposed to etoposide (10 mg/ml) and then their viability was analyzed by trypan blue exclusion assay. Briefly, an aliquot of the cell suspension was diluted 1 : 1 (v/v) with 0.4% trypan blue and the cells were counted with a hemocytometer. Results are expressed as the percentage of dead cells (ratio of stained cells vs. the control number of cells).
DNA Fragmentation Assay Cells were exposed to etoposide (10 mg/ml) overnight and then, harvested and lysed with a buffer containing 20 mM EDTA, 0.8% sodium lauryl sarcosine, 100 mM Tris-HCl, pH 8.0 on ice as described previously. 16) Cell lysates were treated with RNase A, RNase T1, and proteinase K. Following microcentrifugation at 4°C for 15 min, supernatants containing soluble DNA were subjected to phenol/chloroform extraction and ethanol precipitation. The isolated DNA samples were subjected to 1.5% agarose gel electrophoresis, stained with ethidium bromide, and visualized under a UV transilluminator.
Immunocomplex Kinase Assay Cells were exposed to etoposide (10 mg/ml) and then harvested and lysed with a solution containing 50 mM Tris-HCl, pH 7.5, 150 mM sodium chloride, 1 mM phenylmethylsulfonyl fluoride, 1% Nonidet P-40, 0.5% deoxycholate, and 0.1% SDS. After centrifugation, the supernatants were immunoprecipitated with a mouse monoclonal anti-JNK1 antibody (Pharmingen) and the immunopellets were assayed for JNK activity, as described previously. 17) Bacterially expressed GST-c-Jun fusion protein was used as a substrate for the JNK kinase assay. Phosphorylated proteins were separated by SDS-PAGE on 10% polyacrylamide gel and quantified by autoradiography and densitometry. Protein concentrations were determined by the BCA method (Pierce) following the manufacturer's protocol.
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Analysis Total RNA was extracted from the cells using Trizol reagent (Gibco BRL) according to the manufacturer's protocol and the extracted RNA samples were subsequently treated with AMV Reverse transcriptase (Promega). PCRs were performed using specific primers for bcl-xL: forward, 5Ј-gggaagtaaactggggtcgcattgt-3Ј and reverse, 5Ј-gggaatgctgcattgttcccataga-3Ј; bcl-2: forward, 5Јgggaagaggattgtggccttctttg-3Ј and reverse, 5Ј-gggaaacagttccacaaaggcatcc-3Ј; and GAPDH: forward, 5Ј-gggaagagtcaacggatttggtcgt-3Ј and reverse, 5Ј-gggaattgattttggagggatctcg-3Ј. The cycling conditions were 94°C for 5 min, followed by 30 cycles at 94°C for 30 s, at 60°C for 30 s, and at 72°C for 1 min and a final extension at 72°C for 10 min. The PCR products were analyzed by electrophoresis on 1% agarose gel containing ethidium bromide, and photographed under ultraviolet light.
RESULTS

Overexpression of Bcl-xL Represses Etoposide-Induced Cell Death in Neuroglioma N18TG Cells
As expected, etoposide, an anti-cancer drug, induced cell death of the control N18TG (N18/con) cells in a dose-dependent manner (Fig. 1A) . The N18/con cells exposed to 10 mg/ml of etoposide for 24 h showed about 70% of cell death (about 30% of cell viability). The percentage of dead cells that could not exclude trypan blue, increased sharply until 12 h after etoposide (10 mg/ml) treatment and reached about 80% at 36 h after exposure to etoposide (Fig. 1B) . Compared with the N18/con cells, the stable Bcl-xL overexpressing (N18/Bcl-xL) cells significantly suppressed the etoposide-induced cell death (Figs. 1A, B ). Next, we isolated chromosomal DNA from either N18/Bcl-xL or N18/con cells and examined the level of DNA fragmentation that is one of the main apoptotic markers. Upon etoposide treatment, DNA fragmentation was obviously observed in N18/con cells, whereas highly reduced apoptotic DNA fragmentation was found in N18/Bcl-xL cells (Fig. 1C ). To provide further insight into the antiapoptotic pathway of Bcl-xL, we examined the effect of Bcl-xL expression on JNK1 activation under apoptotic condition. Expression of Bcl-xL in N18/Bcl-xL cells resulted in significant repression of etoposide-induced JNK activation, in comparison with that of N18/con cells (Fig. 1D) . These results show that etoposide-induced JNK activation and apoptosis were suppressed by ectopic expression of Bcl-xL in neuroglioma cells.
Overexpression of JNK1 Just Partially Antagonizes the Antiapoptotic Effect of Bcl-xL Next, in order to investigate the relationship between JNK1 overexpression and stable expression of Bcl-xL, a plasmid containing JNK1 (pCEP-JNK1) was transfected into N18/Bcl-xL cells. In the following experiment, we measured the level of etoposide-induced DNA fragmentation in N18/con, N18/Bcl-xL, and N18/Bcl-xL/JNK1 cells. Upon etoposide exposure, the significant level of DNA fragmentation was observed in N18/Bcl-xL/JNK1 cells ( Fig. 2A) . And then, we compared the cell viability of N18/con, N18/Bcl-xL, N18/JNK1, and N18/Bcl-xL/JNK1 cells after etoposide treatment using trypan blue exclusion assay. The N18/Bcl-xL/JNK1 cells showed lower cell viability after etoposide exposure compared with N18/Bcl-xL cells (Fig. 2B) . After etoposide exposure, a slightly higher level of cell death was observed in the N18/JNK1 cells compared with control cells (N18/con). While, the N18/Bcl-xL cells showed a remarkable decrease in etoposide-induced cell death and a similar pattern was observed in N18/Bcl-2 cells (Fig. 3A) . N18/Bcl-2/JNK1 cells showed a significant increase in etoposide-induced cell death, whereas the increase of cell death by expression of JNK1 in N18/Bcl-xL/JNK1 cells was somewhat lower than that in N18/Bcl-2/JNK1 cells (Fig. 3A) . These results indicate that the antiapoptotic effect of Bcl-xL was just partially antagonized by JNK1 overexpression.
Bcl-xL Expression is Induced by JNK1 in N18TG Cells
To investigate the interaction between Bcl-xL and JNK1, we analyzed the activation level of JNK and the expression level of JNK1 or Bcl-xL. Although significant increase of JNK1 expression was observed both in N18/Bcl-xL/JNK1 and N18/Bcl-2/JNK1 cells, apparently lower JNK activation was detected in N18/Bcl-xL/JNK1 cells, compared with that in N18/Bcl-2/JNK1 cells (Fig. 3B) . The stably transfected N18/Bcl-xL/JNK1 cells showed higher etoposide-induced JNK activation than the N18/Bcl-xL cells did (Fig. 3C) . Interestingly, notably higher Bcl-xL expression was observed in N18/Bcl-xL/JNK1 cells independently of JNK activation compared with that in N18/con and N18/Bcl-xL cells (Fig.  3C ). Finally, we could observe that overexpression of JNK1, but not JNK1-DN (dominant-negative) mutant, obviously in-duced the expression of Bcl-xL mRNA, although the expression level of Bcl-2 was not affected by ectopic expression of JNK1 or JNK1-DN (Fig. 3D) . These results indicate that the expression of Bcl-xL may be regulated by JNK1.
DISCUSSION
Recently, targeted gene disruption studies have established that JNK signaling pathway is required for stress-induced release of mitochondrial cytochrome c and apoptotic cell death, 9) and Bcl-2 family proteins are essential for JNK-dependent apoptosis. 18) By now, three subfamilies of Bcl-2 proteins have been reported to play important roles in the apoptotic response. The Bcl-2 subfamily proteins such as Bcl-2 and Bcl-xL inhibit apoptosis, while the Bcl-2-associated (Bax) subfamily proteins such as Bax, Bak, Bok, and Bcl-xS and the BH3-only subfamily including Bid, Bad, Bik, Bim, Bmf, Noxa, and Puma promote apoptosis. 19) The suggested mechanisms by which the Bcl-2 family proteins function include regulation of mitochondrial integrity 20) and pore formation. 21, 22) Moreover, the phosphorylation of Bcl-2 family members has been reported to regulate their function. 18, [23] [24] [25] [26] [27] [28] [29] The bcl-x gene is known to produce two protein products, Bcl-xL and Bcl-xS by alternative mRNA splicing mechanism. 13) Expression of larger form of bcl-x, bcl-xL, resulted in inhibition of cell death, while that of the bcl-xS inhibited 1688 Vol. 31, No. 9
Fig. 1. The Expression of Bcl-xL in N18TG Cells Results in Suppression of Cell Death Induced by Etoposide
Neuroglioma N18TG cells were transfected with either a control vector or a vector containing bcl-xL. (A) N18 control cells (N18/con) and Bcl-xL-expressing cells (N18/Bcl-xL) were exposed to etoposide (0.1-10 mg/ml) for 4 h and then further incubated overnight. Cell viability of either control or Bcl-xL-expressing cells was measured by trypan blue exclusion assay. (B) Cells were exposed to etoposide (10 mg/ml) for 4 h and then further incubated for the time indicated in Figure. (C) Cells were exposed to etoposide (10 mg/ml) for the ability of Bcl-2. Bcl-xL is overexpressed in human cancer and detected in tissues containing long-lived postmitotic cells such as adult brain, whereas Bcl-xS was expressed at high levels in cells that undergo a high rate of turnover such as developing lymphocytes. 19) In this study, expression of Bcl-xL was found to repress the etoposide-induced cell death and DNA fragmentation as well as JNK stimulation (Fig. 1) . Moreover, when JNK1 was overexpressed, DNA fragmentation and JNK activation induced by etoposide were increased even in the presence of Bcl-xL ( Figs. 2A, 3C) . The antiapop- totic effect of Bcl-xL, however, was just partially antagonized by JNK1 overexpression (Figs. 2B, 3A) .
By now, several signaling pathways involving JNK signaling cascade have been proposed for regulatory mechanism of the antiapoptotic action of Bcl-xL. In this study, stable expression of JNK1 partially overcame the antiapoptotic environment attained by overexpression of Bcl-xL. Previous study reported that sustained activation of JNK1 almost completely overcame the antiapoptotic effect of Bcl-2, suggesting that JNK has a pivotal role on the antiapoptotic function of Bcl-2 family. 30) Compared to the case with Bcl-2, stable expression of JNK1, however, did not sufficiently antagonize the effect of Bcl-xL (Fig. 3A) . Therefore, our results showed the possibility that the Bcl-xL or Bcl-2 induces its antiapoptotic effect through a different mechanism and the antiapoptotic action of Bcl-xL is less dependent on JNK1-involved pathway. Additional study showed that overexpression of JNK1 led to increase of the Bcl-xL expression ( Fig. 3D) . Taken together, our data suggest that the JNK1-involved pathway may differentially regulate the antiapoptotic action of Bcl-xL and Bcl-2 in neuroglioma N18TG cells, prompting the possibility of involvement of JNK1 in Bcl-xL expression.
Although the importance of the functional interaction between JNK1 and Bcl-2 family proteins was reported, any previous studies on the regulatory function of Bcl-2 or Bcl-xL proteins could not show clear explanation for the redundant existence of Bcl-2 family proteins. Previous reports showed that multiple kinases including PKC and Erk mediated the phosphorylation of Bcl-2 following various stimuli. [31] [32] [33] [34] Moreover, the antiapoptotic proteins Bcl-2 and Bcl-xL have been identified to be phosphorylated and inactivated by JNK 24, 31, [34] [35] [36] and inhibition of JNK activity has been revealed to prevent Bcl-2 phosphorylation and apoptosis. In contrary to Bcl-2 which is phosphorylated on multiple Ser/Thr residues, Bcl-xL is phosphorylated on single or two serine residues following taxol exposure. 25) The precise functional roles of Bcl-2 or Bcl-xL phosphorylation and their differential phosphorylation pattern, however, remain uncertain. Further work will be required to address whether the effect of Bcl-2 family proteins is dependent on the differential regulation of phosphorylation or transcription by JNK pathway and the detailed underlying signaling mechanism by which JNK contributes to promote differential expression of Bcl-2 family proteins.
